强生-话题@MedSci

#强生#

169篇内容 | 4612人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1271625, encodeId=dd3f12e162503, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=麻省总医院和强生合作将瞄准癌细胞的芯片商业化, objectType=article, longId=31761, objectId=a9ea31e618d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9ea31e618d, replyNumber=0, likeNumber=90, createdTime=2014-03-13, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9ea31e618d, moduleTitle=麻省总医院和强生合作将瞄准癌细胞的芯片商业化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9ea31e618d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271624, encodeId=ebfa12e1624c0, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生结核新药Situro获欧盟有条件批准, objectType=article, longId=31689, objectId=fbaa3168964, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbaa3168964, replyNumber=0, likeNumber=54, createdTime=2014-03-12, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbaa3168964, moduleTitle=强生结核新药Situro获欧盟有条件批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbaa3168964)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271623, encodeId=8e6212e1623a9, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=瞄准癌细胞的芯片：麻省总医院和强生合作将其商业化, objectType=article, longId=31633, objectId=1cbc3163345, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1cbc3163345, replyNumber=0, likeNumber=60, createdTime=2014-03-09, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1cbc3163345, moduleTitle=瞄准癌细胞的芯片：麻省总医院和强生合作将其商业化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1cbc3163345)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271622, encodeId=65fc12e16227b, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=CHMP建议批准强生糖尿病新药VOKANAMET, objectType=article, longId=31075, objectId=1349310e5c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1349310e5c7, replyNumber=0, likeNumber=64, createdTime=2014-02-26, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1349310e5c7, moduleTitle=CHMP建议批准强生糖尿病新药VOKANAMET, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1349310e5c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271621, encodeId=cc8712e162102, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生拜瑞妥（Xarelto）ACS适应症遭FDA拒绝, objectType=article, longId=30710, objectId=226d30e1046, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=226d30e1046, replyNumber=0, likeNumber=56, createdTime=2014-02-19, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=226d30e1046, moduleTitle=强生拜瑞妥（Xarelto）ACS适应症遭FDA拒绝, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=226d30e1046)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271620, encodeId=a2d812e162014, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生抗癌药Imbruvica新适应症获FDA批准, objectType=article, longId=30690, objectId=db57306904b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db57306904b, replyNumber=0, likeNumber=63, createdTime=2014-02-18, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db57306904b, moduleTitle=强生抗癌药Imbruvica新适应症获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db57306904b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271619, encodeId=1a7f12e16195d, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生单抗药Stelara获加拿大批准, objectType=article, longId=29875, objectId=8442298e51c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8442298e51c, replyNumber=0, likeNumber=72, createdTime=2014-01-25, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8442298e51c, moduleTitle=强生单抗药Stelara获加拿大批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8442298e51c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271618, encodeId=ad4a12e1618cc, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生拜瑞妥（Xarelto）ACS适应症遭FDA委员会否决, objectType=article, longId=29560, objectId=299929560b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=299929560b7, replyNumber=0, likeNumber=73, createdTime=2014-01-19, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=299929560b7, moduleTitle=强生拜瑞妥（Xarelto）ACS适应症遭FDA委员会否决, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=299929560b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271617, encodeId=e3d012e161786, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=FDA对强生拜瑞妥（Xarelto）ACS适应症持谨慎态度, objectType=article, longId=29502, objectId=cad6295023e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cad6295023e, replyNumber=0, likeNumber=57, createdTime=2014-01-18, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cad6295023e, moduleTitle=FDA对强生拜瑞妥（Xarelto）ACS适应症持谨慎态度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cad6295023e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271616, encodeId=ed6a12e161613, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=CHMP建议有条件批准强生结核病药物Sirturo, objectType=article, longId=28634, objectId=bee9286347e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bee9286347e, replyNumber=0, likeNumber=68, createdTime=2013-12-28, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bee9286347e, moduleTitle=CHMP建议有条件批准强生结核病药物Sirturo, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bee9286347e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271615, encodeId=51ee12e161580, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生旗下TB药物Sirturo获欧盟支持梯瓦制药旗下MS药物Laquinimod被推迟, objectType=article, longId=28550, objectId=417d2855055, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=417d2855055, replyNumber=0, likeNumber=69, createdTime=2013-12-27, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=417d2855055, moduleTitle=强生旗下TB药物Sirturo获欧盟支持梯瓦制药旗下MS药物Laquinimod被推迟, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=417d2855055)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271614, encodeId=629212e16141c, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=FDA拒绝批准强生旗下糖尿病复方药物, objectType=article, longId=28239, objectId=3ffb28239b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ffb28239b8, replyNumber=0, likeNumber=59, createdTime=2013-12-20, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ffb28239b8, moduleTitle=FDA拒绝批准强生旗下糖尿病复方药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ffb28239b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271612, encodeId=ee0f12e16120d, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生丙肝新药OLYSIO（simeprevir）获FDA批准, objectType=article, longId=27073, objectId=5ca32e07362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ca32e07362, replyNumber=0, likeNumber=61, createdTime=2013-11-27, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ca32e07362, moduleTitle=强生丙肝新药OLYSIO（simeprevir）获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ca32e07362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271613, encodeId=6a9b12e161300, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生糖尿病新药INVOKANA获欧盟批准, objectType=article, longId=27074, objectId=00f42e07433, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00f42e07433, replyNumber=0, likeNumber=83, createdTime=2013-11-27, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00f42e07433, moduleTitle=强生糖尿病新药INVOKANA获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00f42e07433)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271611, encodeId=fabc12e16119c, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生淋巴瘤药物Imbruvia获FDA批准, objectType=article, longId=26621, objectId=f9d526621ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9d526621ee, replyNumber=0, likeNumber=81, createdTime=2013-11-16, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9d526621ee, moduleTitle=强生淋巴瘤药物Imbruvia获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9d526621ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271610, encodeId=81d512e161013, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生就回扣营销与美国政府达成22亿美元和解, objectType=article, longId=26260, objectId=bc76262609c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc76262609c, replyNumber=0, likeNumber=57, createdTime=2013-11-07, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc76262609c, moduleTitle=强生就回扣营销与美国政府达成22亿美元和解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc76262609c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271609, encodeId=7a5312e160945, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生向欧盟提交血癌药物Ibrutinib上市许可申请, objectType=article, longId=26141, objectId=92da26141bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92da26141bf, replyNumber=0, likeNumber=77, createdTime=2013-11-03, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92da26141bf, moduleTitle=强生向欧盟提交血癌药物Ibrutinib上市许可申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92da26141bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271608, encodeId=e8d412e160896, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=FDA顾问委员会建议批准强生丙肝新药simeprevir, objectType=article, longId=25828, objectId=ed8925828a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed8925828a9, replyNumber=0, likeNumber=58, createdTime=2013-10-27, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed8925828a9, moduleTitle=FDA顾问委员会建议批准强生丙肝新药simeprevir, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed8925828a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271607, encodeId=efc712e160749, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生丙肝新药simeprevir获FDA审查员积极意见, objectType=article, longId=25761, objectId=130d25e61ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=130d25e61ea, replyNumber=0, likeNumber=67, createdTime=2013-10-26, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=130d25e61ea, moduleTitle=强生丙肝新药simeprevir获FDA审查员积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=130d25e61ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271606, encodeId=91e612e16063d, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生向欧洲提交新的艾滋病复方药物上市申请, objectType=article, longId=25608, objectId=450d25608cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=450d25608cd, replyNumber=0, likeNumber=73, createdTime=2013-10-23, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=450d25608cd, moduleTitle=强生向欧洲提交新的艾滋病复方药物上市申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=450d25608cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

强生

2020-05-29

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

麻省总医院和强生合作将瞄准癌细胞的芯片商业化

2014-03-13

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生结核新药Situro获欧盟有条件批准

2014-03-12

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

瞄准癌细胞的芯片：麻省总医院和强生合作将其商业化

2014-03-09

爆笑小医 (审核中...)

前往app查看评论内容

#强生#

CHMP建议批准强生糖尿病新药VOKANAMET

2014-02-26

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生拜瑞妥（Xarelto）ACS适应症遭FDA拒绝

2014-02-19

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生抗癌药Imbruvica新适应症获FDA批准

2014-02-18

docwu2019 (审核中...)

前往app查看评论内容

#强生#

强生单抗药Stelara获加拿大批准

2014-01-25

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生拜瑞妥（Xarelto）ACS适应症遭FDA委员会否决

2014-01-19

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

FDA对强生拜瑞妥（Xarelto）ACS适应症持谨慎态度

2014-01-18

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

CHMP建议有条件批准强生结核病药物Sirturo

2013-12-28

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生旗下TB药物Sirturo获欧盟支持梯瓦制药旗下MS药物Laquinimod被推迟

2013-12-27

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

FDA拒绝批准强生旗下糖尿病复方药物

2013-12-20

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生丙肝新药OLYSIO（simeprevir）获FDA批准

2013-11-27

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生糖尿病新药INVOKANA获欧盟批准

2013-11-27

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生淋巴瘤药物Imbruvia获FDA批准

2013-11-16

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生就回扣营销与美国政府达成22亿美元和解

2013-11-07

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生向欧盟提交血癌药物Ibrutinib上市许可申请

2013-11-03

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

FDA顾问委员会建议批准强生丙肝新药simeprevir

2013-10-27

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生丙肝新药simeprevir获FDA审查员积极意见

2013-10-26

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生向欧洲提交新的艾滋病复方药物上市申请

2013-10-23

科室
- - 订阅+
  - 更多科室
工具
服务